Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

• Status: Recruiting
• Trial end date: 2023-03-30
• Target enrollment: 0
• Participant gender: Female

Summary

This novel study was specifically designed for platinum resistant recurrent ovarian cancers and aimed to compare cases who received secondary cytoreductive surgery for isolated recurrence and chemotherapy versus chemotherapy alone. This comparison will conduct the intraoperative events, postoperative morbidity and mortality, pathological outcomes and long-term oncological outcomes as regarding progression free survival and overall survival rates.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Menoufia University

Criteria

Inclusion Criteria:

• platinum-resistant, recurrent epithelial ovarian cancer

• amenable to complete gross resection, isolated recurrence

• adequate renal, hepatic, and bone marrow function,

• performance-status ECOG score of 0 to 2.

Exclusion Criteria:

• not medically fit for surgery

• diffuse carcinomatosis, ascites, or extra-abdominal disease